α2-Antiplasmin As a Potential Therapeutic Target for Systemic Sclerosis

Overview

Journal Life (Basel)

Specialty Biology

Date 2022 Mar 25

PMID 35330147

Authors

Yosuke Kanno

En Shu

Affiliations

Soon will be listed here.

Abstract

Systemic sclerosis is a connective tissue disease of unknown origin that is characterized by immune system abnormalities, vascular damage, and extensive fibrosis of the skin and visceral organs. α2-antiplasmin is known to be the main plasmin inhibitor and has various functions such as cell differentiation and cytokine production, as well as the regulation of the maintenance of the immune system, endothelial homeostasis, and extracellular matrix metabolism. The expression of α2-antiplasmin is elevated in dermal fibroblasts from systemic sclerosis patients, and the blockade of α2-antiplasmin suppresses fibrosis progression and vascular dysfunction in systemic sclerosis model mice. α2-antiplasmin may have promise as a potential therapeutic target for systemic sclerosis. This review considers the role of α2-antiplasmin in the progression of systemic sclerosis.

Citing Articles

Cuproptosis Cell Death Molecular Events and Pathways to Liver Disease.

Mao Y, Chen H, Zhu W, Ni S, Luo S, Tang S J Inflamm Res. 2025; 18:883-894.

PMID: 39867947 PMC: 11760270. DOI: 10.2147/JIR.S498340.

Enhanced sclerotherapy for vascular malformations: A dual-mechanism approach using in-situ forming PATDs gel.

Ma J, Li W, Ding Y, Chen Y, Huang X, Yu T Mater Today Bio. 2024; 29:101376.

PMID: 39698002 PMC: 11653148. DOI: 10.1016/j.mtbio.2024.101376.

Impact of Plasminogen Activator Inhibitor-1 Serum Levels and the -675 4G/5G Variant in the SERPINE1 Gene on Systemic Sclerosis in a Mexican Population.

Lomeli-Nieto J, Munoz-Valle J, Navarro-Zarza J, Banos-Hernandez C, Gutierrez-Brito J, Renteria-Cabrera V Life (Basel). 2024; 14(9).

PMID: 39337840 PMC: 11433212. DOI: 10.3390/life14091056.

α2-Antiplasmin is associated with macrophage activation and fibrin deposition in a macrophage activation syndrome mouse model.

Kanno Y, Toyama K, Shibata H, Matsuo O, Ozaki K Clin Exp Immunol. 2024; 216(3):272-279.

PMID: 38457368 PMC: 11097911. DOI: 10.1093/cei/uxae021.

Research progress on the fibrinolytic enzymes produced from traditional fermented foods.

Wang P, Peng C, Xie X, Deng X, Weng M Food Sci Nutr. 2023; 11(10):5675-5688.

PMID: 37823145 PMC: 10563737. DOI: 10.1002/fsn3.3601.

References

Manetti M, Guiducci S, Ibba-Manneschi L, Matucci-Cerinic M . Mechanisms in the loss of capillaries in systemic sclerosis: angiogenesis versus vasculogenesis. J Cell Mol Med. 2010; 14(6A):1241-54. PMC: 3828842. DOI: 10.1111/j.1582-4934.2010.01027.x. View

Ma S, Wang S, Li M, Zhang Y, Zhu P . The effects of pigment epithelium-derived factor on atherosclerosis: putative mechanisms of the process. Lipids Health Dis. 2018; 17(1):240. PMC: 6192115. DOI: 10.1186/s12944-018-0889-z. View

Xing X, Li A, Tan H, Zhou Y . IFN-γ IL-17 Th17 cells regulate fibrosis through secreting IL-21 in systemic scleroderma. J Cell Mol Med. 2020; 24(23):13600-13608. PMC: 7753990. DOI: 10.1111/jcmm.15266. View

LeBleu V, Taduri G, OConnell J, Teng Y, Cooke V, Woda C . Origin and function of myofibroblasts in kidney fibrosis. Nat Med. 2013; 19(8):1047-53. PMC: 4067127. DOI: 10.1038/nm.3218. View

Kanno Y, Sakai A, Miyashita M, Tsuchida K, Matsuo O . Plasminogen deficiency is associated with improved glucose tolerance, and lower DPP-4 activity. Diabetes Res Clin Pract. 2016; 120:190-3. DOI: 10.1016/j.diabres.2016.08.007. View

OReilly S, Hugle T, van Laar J . T cells in systemic sclerosis: a reappraisal. Rheumatology (Oxford). 2012; 51(9):1540-9. DOI: 10.1093/rheumatology/kes090. View

Kanno Y . The Role of Fibrinolytic Regulators in Vascular Dysfunction of Systemic Sclerosis. Int J Mol Sci. 2019; 20(3). PMC: 6387418. DOI: 10.3390/ijms20030619. View

Tombran-Tink J, Aparicio S, Xu X, Tink A, Lara N, Sawant S . PEDF and the serpins: phylogeny, sequence conservation, and functional domains. J Struct Biol. 2005; 151(2):130-50. DOI: 10.1016/j.jsb.2005.05.005. View

Lijnen H, Van Hoef B, Collen D . Inactivation of the serpin alpha(2)-antiplasmin by stromelysin-1. Biochim Biophys Acta. 2001; 1547(2):206-13. DOI: 10.1016/s0167-4838(01)00186-8. View

10.

Kanno Y, Tsuchida K, Maruyama C, Hori K, Teramura H, Asahi S . Alpha2-antiplasmin deficiency affects depression and anxiety-like behavior and apoptosis induced by stress in mice. J Basic Clin Physiol Pharmacol. 2021; 33(5):633-638. DOI: 10.1515/jbcpp-2021-0282. View

11.

Sanges S, Guerrier T, Launay D, Lefevre G, Labalette M, Forestier A . Role of B cells in the pathogenesis of systemic sclerosis. Rev Med Interne. 2016; 38(2):113-124. DOI: 10.1016/j.revmed.2016.02.016. View

12.

Trejo J . Protease-activated receptors: new concepts in regulation of G protein-coupled receptor signaling and trafficking. J Pharmacol Exp Ther. 2003; 307(2):437-42. DOI: 10.1124/jpet.103.052100. View

13.

Tomimura S, Ogawa F, Iwata Y, Komura K, Hara T, Muroi E . Autoantibodies against matrix metalloproteinase-1 in patients with localized scleroderma. J Dermatol Sci. 2008; 52(1):47-54. DOI: 10.1016/j.jdermsci.2008.04.013. View

14.

Gilbane A, Denton C, Holmes A . Scleroderma pathogenesis: a pivotal role for fibroblasts as effector cells. Arthritis Res Ther. 2013; 15(3):215. PMC: 4060542. DOI: 10.1186/ar4230. View

15.

Deryugina E, Quigley J . Cell surface remodeling by plasmin: a new function for an old enzyme. J Biomed Biotechnol. 2012; 2012:564259. PMC: 3477900. DOI: 10.1155/2012/564259. View

16.

Niwa H, Kanno Y, Shu E, Seishima M . Decrease in matrix metalloproteinase‑3 activity in systemic sclerosis fibroblasts causes α2‑antiplasmin and extracellular matrix deposition, and contributes to fibrosis development. Mol Med Rep. 2020; 22(4):3001-3007. DOI: 10.3892/mmr.2020.11358. View

17.

Davalos D, Akassoglou K . Fibrinogen as a key regulator of inflammation in disease. Semin Immunopathol. 2011; 34(1):43-62. DOI: 10.1007/s00281-011-0290-8. View

18.

Yoshizaki A, Komura K, Iwata Y, Ogawa F, Hara T, Muroi E . Clinical significance of serum HMGB-1 and sRAGE levels in systemic sclerosis: association with disease severity. J Clin Immunol. 2008; 29(2):180-9. DOI: 10.1007/s10875-008-9252-x. View

19.

Reed G, Houng A, Wang D . Microvascular thrombosis, fibrinolysis, ischemic injury, and death after cerebral thromboembolism are affected by levels of circulating α2-antiplasmin. Arterioscler Thromb Vasc Biol. 2014; 34(12):2586-93. PMC: 4239309. DOI: 10.1161/ATVBAHA.114.304530. View

20.

Lemaire R, Burwell T, Sun H, Delaney T, Bakken J, Cheng L . Resolution of Skin Fibrosis by Neutralization of the Antifibrinolytic Function of Plasminogen Activator Inhibitor 1. Arthritis Rheumatol. 2015; 68(2):473-83. DOI: 10.1002/art.39443. View